Macugen
(Pegaptanib sodium)ApprovedSmall molecule
PfizerPegaptanib sodium is used to treat a type of vision loss caused by wet age-related macular degeneration, a disease where abnormal blood vessels grow under the retina and damage central vision in older adults.[2] Macugen is currently approved and in use across 14 indications[4].[1]
Macugen is one of 189 small molecule programs targeting X-linked reticulate pigmentary disorder with systemic manifestations. It is currently in Approved.
14
Indications
20
Total Trials
0
Active Trials
188
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 14 indications
Competition
Competitive Landscape
237 competitors in Age-Related Macular Degeneration
#DrugCompanyPhaseTrials
1Eylea
RegeneronPhase 3
Lucentis
RochePhase 3
Macugen
PfizerApproved
Vabysmo
RochePhase 3
Beovu
NovartisPhase 3
Avastin
BBio-Thera Solutions
Phase 3
Retaane
AAlcon Research
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Forzinity
SStealth BioTherapeutics Inc.
Phase 3
Luye Pharma Conbercept
CChengdu Kanghong Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Age-Related Macular Degeneration6 trials
Safety and Efficacy2 trials
Retinal Vein Occlusion2 trials
7 more indications
Cystoid Macular Edema1 trial
Neovascular AMD1 trial
DME1 trial
Cataract1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Macugen drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Pegaptanib sodium. EMBL-EBI & Wellcome Sanger Institute.
- [5]